Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Aged 18 Years and Above
NCT06645665 is registered in ClinicalTrials.gov with Shenzhen Shenxin Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Aged 18 Years and Above
- Lead sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- November 11, 2024
- Completion date
- April 30, 2027
- Enrollment
- 240 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.